Abstract
In light of remaining therapeutic challenges in the management of hemophilia, research continues to be conducted into the use of various technologies that could potentially improve therapy with factor concentrates. One improvement that is currently being investigated is the prolongation of the half-life of factor concentrates, making the factor concentrate longer-acting and potentially decreasing the number of injections administered to the person with hemophilia. These technologies include PEGylation, which is the chemical modification of proteins with synthetic polyethylene glycol derivatives. Another technology being explored is the use of polysialic acid addition. Polysialylation by linking polysaccharide chains to the amino acids of the protein affects the pharmacokinetics of therapeutic proteins including prolonging half-life.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Turecek, P.L. et al. (2008). Novel Strategies for FVIII: Half-life Prolongation. In: Scharrer, I., Schramm, W. (eds) 37th Hemophilia Symposium. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-73535-9_5
Download citation
DOI: https://doi.org/10.1007/978-3-540-73535-9_5
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-73534-2
Online ISBN: 978-3-540-73535-9
eBook Packages: MedicineMedicine (R0)